血液病合并毛霉菌病七例报告及文献复习
回顾性分析2012年9月至2018年9月7例血液病合并毛霉菌病患者的临床资料。7例均经活检组织病理确诊,治疗采用两性霉素B或脂质体及泊沙康唑,4例手术。治愈2例、好转1例、死亡4例。结论强调早期诊断、控制基础疾病、有效抗真菌治疗及彻底手术清创是提高生存率的关键。
要点
- 血液病合并毛霉菌病临床表现及影像学表现多样,死亡率高。
- 确诊主要依赖活检组织病理学。
- 早期诊断、控制基础疾病、有效抗真菌治疗及彻底手术清创是提高生存率的关键。
核心结论
- 血液病合并毛霉菌病患者临床表现及影像学表现多样,死亡率高,确诊主要依赖于组织病理学。
- 早期诊断、控制基础疾病、改善免疫抑制状态、尽早行有效的抗真菌药物治疗及彻底的手术清创治疗是提高生存率的关键。
研究设计与样本
- 回顾性分析2012年9月至2018年9月7例血液病合并毛霉菌病患者的临床资料,分析其临床特征、治疗过程和转归。
主要发现
- 7例患者中男4例、女3例,中位年龄36(19~79)岁。
- 基础疾病:急性髓系白血病2例,急性B淋巴细胞白血病、外周T细胞淋巴瘤、慢性髓性白血病急髓变、骨髓增殖性肿瘤及重型再生障碍性贫血(移植后)各1例。
- 毛霉菌病临床类型:肺型4例,鼻眶脑型1例,皮肤型1例,播散型1例。
- 7例患者均通过活检组织病理确诊。
- 治疗药物为两性霉素B、两性霉素B脂质体及泊沙康唑;手术治疗4例,其中3例术中彻底清除病变组织,1例仅行局限性清除;治愈2例,好转1例,死亡4例。
临床怎么用
- 对血液病合并毛霉菌病患者应尽早行活检组织病理确诊。
- 治疗需控制基础疾病、改善免疫抑制状态,并尽早使用有效抗真菌药物。
- 对适合的患者行彻底的手术清创治疗以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical characteristics, diagnosis, treatment and prognosis of patients with hematological diseases that complicated by mucormycosis, and to improve the understanding and clinical diagnosis and treatment of the disease. Methods: The clinical data of 7 patients suffering from mucormycosis during September 2012 and September 2018 were retrospectively analyzed, and their clinical characteristics, treatment process and prognosis were analyzed. Results: Of 7 patients, there were 4 males and 3 females, with a median age of 36 (19-79) years old. Two patients were diagnosed as acute myeloid leukemia as the underlying disease, the other 5 patients suffered from acute B lymphoblastic leukemia, peripheral T cell lymphoma, chronic myelocytic leukemia in blastic phase, myeloproliferative neoplasm and severe aplastic anemia after transplantation, respectively. Among them, disease types of mucormycosis were pulmonary in 4 patients, rhino-orbital-cerebral in 1 patient, cutaneous in 1 patient and disseminated in 1 patient. All the cases were confirmed by biopsy histopathology. The treatment drugs were amphotericin B or liposomal amphotericin B, and posaconazole. Surgical treatment was performed in 4 patients, 3 out of 4 achieved radical debridement, and the other one had local debridement. Two patients were cured, 1 patient was improved and 4 patients died. Conclusions: The clinical manifestation and image feature of mucormycosis in patients with hematological diseases were diverse, and the mortality rate is high, diagnosis mainly depends on histopathology. Early diagnosis, control of underlying disease, improvement of immunosuppressive status, timely effective antifungal therapy and radical surgical debridement are the key points for improving the survival rate of patients with hematological diseases complicated by mucormycosis. 目的: 探讨血液病合并毛霉菌病患者的临床特征、诊治与转归,提高对该病的认识。 方法: 回顾性分析2012年9月至2018年9月7例血液病合并毛霉菌病患者的临床资料,分析其临床特征、治疗过程和转归。 结果: 7例血液病合并毛霉菌病患者中,男4例,女3例,中位年龄36(19~79)岁。基础疾病:急性髓系白血病2例,急性B淋巴细胞白血病、外周T细胞淋巴瘤、慢性髓性白血病急髓变、骨髓增殖性肿瘤及重型再生障碍性贫血(移植后)各1例。毛霉菌病临床类型:4例为肺型,1例为鼻眶脑型,1例为皮肤型,1例为播散型。7例患者均通过活检组织病理确诊。治疗药物为两性霉素B、两性霉素B脂质体及泊沙康唑。手术治疗4例,其中3例术中彻底清除病变组织,1例仅行局限性清除。治愈2例,好转1例,死亡4例。 结论: 血液病合并毛霉菌病患者临床表现及影像学表现多样,死亡率高,确诊主要依赖于组织病理学。早期诊断、控制基础疾病、改善免疫抑制状态、尽早行有效的抗真菌药物治疗及彻底的手术清创治疗是提高血液病合并毛霉菌病患者生存率的关键。.
引用
- Qi Y, Zhao MF, Deng Q, et al. [Mucormycosis in patients with hematological diseases: seven cases reports and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856445. doi:10.3760/cma.j.issn.0253-2727.2019.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。